| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Lenvatinib, sintilimab combined interventional treatment vs bevacizumab, sintilimab combined interventional treatment for intermediate-advanced unresectable hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ru-Yu Han, Lei-Juan Gan, Meng-Ran Lang, Shao-Hua Ren, Dong-Ming Liu, Guang-Tao Li, Ya-Yue Liu, Xin-Di Tian, Kang-Wei Zhu, Li-Yu Sun, Lu Chen and Tian-Qiang Song |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| The National Natural Science Foundation of China |
82173317 |
| The Scientific Research Projects of Tianjin Education Commission |
2022KJ227 |
| The Doctoral Start-up Fund of Tianjin Medical University Cancer Institute & Hospital |
B2208 |
|
| Corresponding Author |
Tian-Qiang Song, MD, PhD, Professor, Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, West Huanhu Road, Tiyuanbei, Hexi District, Tianjin 300060, China. songtianqiangtj@163.com |
| Key Words |
Hepatocellular carcinoma; Molecular targeted therapy; Immunotherapy; Interventional treatment; Propensity score matching |
| Core Tip |
In this study, we compared the efficacy and safety of two treatments [bevacizumab plus sintilimab plus interventional treatment (BeSiIT) and lenvatinib plus sintilimab plus interventional treatment (LeSiIT)] in intermediate to advanced hepatocellular carcinoma (HCC). In this study, we found that the triple combination of BeSiIT and LeSiIT improved the prognosis of intermediate- and advanced-stage HCC, with comparable efficacy and acceptable toxicity for both treatments. And a novel marker was identified: Alpha-fetoprotein and carcinoembryonic antigen score. It was shown to be an independent prognostic factor associated with progression-free survival in multivariate analysis. |
| Publish Date |
2024-10-31 10:42 |
| Citation |
<p>Han RY, Gan LJ, Lang MR, Ren SH, Liu DM, Li GT, Liu YY, Tian XD, Zhu KW, Sun LY, Chen L, Song TQ. Lenvatinib, sintilimab combined interventional treatment vs bevacizumab, sintilimab combined interventional treatment for intermediate-advanced unresectable hepatocellular carcinoma. <i>World J Gastroenterol</i> 2024; 30(43): 4620-4635</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i43/4620.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i43.4620 |
